



## Agenda




Time	Subject	Presenter
8:00AM	Breakfast and Registration	
8:30AM	Welcome	Robert Burrows, VP Investor Relations
8:35AM	Corporate Growth Strategy & 2020 Plan	Daniel Abdun-Nabi, President & CEO
8:45AM	U.S. Government Perspective on Public Health Threats	Congressman Mike Rogers (retired) Introduction by Chris Frech, SVP Global Government Affairs
9:45AM	U.S./ROW Market Opportunity	Darren Buchwald, SVP Sales & Marketing
10:10AM	Break	
10:20AM	Emergent Business Units	Adam Havey, EVP Business Operations Laura Saward, Ph.D., SVP Antibody Therapeutics Doug White, SVP Devices Sean Kirk, SVP Contract Manufacturing Operations
11:20AM	R&D: Pipeline Overview and External Funding Strategy	Jim Jackson, Ph.D., SVP & CSO Barb Solow, Ph.D., SVP External Development & Government Contracting
11:45M	M&A Pipeline and Strategy	Atul Saran, EVP Corporate Development & General Counsel
12:10PM	Financial Update	Robert Kramer, Sr., EVP Administration & CFO
12:25PM	Closing	Daniel Abdun-Nabi, President & CEO
12:30PM	Adjourn	

### Robert G. Burrows







Mr. Burrows received his M.B.A. in Public and Non-Profit Management from Boston University and his B.A. in Art History and Studio Art from The University of California, Davis.



### Daniel J. Abdun-Nabi







Mr. Abdun-Nabi has served as chief executive officer since April 2012, as president since March 2007, and as a board member since May 2009. He previously served as chief operating officer from May 2007 through March 2012. Mr. Abdun-Nabi served as senior vice president corporate affairs and general counsel from December 2004 to April 2007, secretary from December 2004 to January 2008, and vice president and general counsel from May 2004 to December 2004.

Prior to joining the company, Mr. Abdun-Nabi served as general counsel for IGEN International, Inc., a biotechnology company, and its successor BioVeris Corporation, from September 1999 to May 2004, and as senior vice president, legal affairs, general counsel and secretary of North American Vaccine, Inc.

Mr. Abdun-Nabi received a Master of Laws in taxation from Georgetown University Law Center, a J.D. from the University of San Diego School of Law and a B.A. in political science from the University of Massachusetts, Amherst.

### Christopher W. Frech





#### Senior Vice President, Global Government Affairs

Chris is responsible for managing global government affairs, public policy, community engagement, and the Emergent BioSolutions employees PAC. He first joined the company in February of 2009 as the vice president of government affairs.

Prior to joining Emergent, Chris established himself as an experienced senior government official with more than 15 years of legislative experience. He served in the George W. Bush Administration as the deputy assistant to the president for legislative affairs, overseeing and managing the House legislative affairs team. He served as President Bush's chief liaison to the House of Representatives from January 2008 to January 2009, where he was responsible for providing legislative, strategic, and tactical advice to the president, vice president, cabinet and White House senior staff on all issues relating to working with the Congress to enact his priorities and policy objectives. In September 2003, Chris began serving as special assistant to the president, responsible for dealing with 85 Members of Congress from both political parties. He was the primary liaison for five separate committees covering financial services, judiciary, government operations, homeland security, and science and technology. Chris managed legislative strategy for several major initiatives, including: Immigration Reform, Foreign Intelligence Surveillance Reform, Postal Reform, Patriot Act Reauthorization, Terrorism Risk Insurance Program, and Government Sponsored Enterprises Reform.

Prior to his service to the President, Chris was the deputy chief of staff and rules committee associate for the Honorable Deborah Pryce, who represented Ohio's 15th Congressional District. Chris served with her for almost eleven years. As a senior staff member, he was responsible for managing a variety of the Congresswoman's policy issues and political activities. Chris also served as the special assistant to the chairman of the House Republican Conference. he managed conference operations and logistics and was a chief liaison to the Republican members of the House. After the 1994 elections, Chris was detailed to the Minority Whip's office to provide support for the office of the Honorable Newt Gingrich (R-GA), Speaker-elect of the House of Representatives.

Chris received a B.A. in International Studies from Wheeling Jesuit University, in Wheeling, West Virginia, and completed his M.A. in Public Policy with a concentration in international public policy and policy analysis at West Virginia University, in Morgantown. Chris participated in the University of New Orleans program in Belgium where he studied French, European Civilization, and worked on restoration of a 12th century Château. In 1988, Chris attended the Georgetown University summer session and studied modern middle-eastern military conflict and strategy.



# Honorable Mike Rogers,

U.S. House of Representatives (MI) (retired)

As former chairman of the U.S. House Permanent Select Committee on Intelligence, Mike Rogers spent over a decade shaping critical cybersecurity, counterterrorism and national security policies in the United States and dealt with some of the most sensitive issues to face the nation. He is widely respected by both Republicans and Democrats for his leadership—Washington Post columnist David Ignatius called him "a rare example of bipartisanship."

Today, he remains at the center of crucial debates on critical issues serving as a regular CNN national security commentator. He is the host and executive producer of the CNN documentary-style original series Declassified where he offers viewers unprecedented, behind-the-scenes access to America's most covert and newly declassified missions across the globe. Rogers gained additional insider perspective traveling the globe, and his invaluable insight and experience help both individuals and organizations better understand the critical issues that impact their daily lives and operations.

As a former member of the U.S. Congress representing Michigan's 8th Congressional District, officer in the U.S. Army, and special agent in the FBI, Rogers is uniquely positioned to influence national discussions and offer expert analysis on diverse political and national security-related subjects. Rogers brings astute and relevant insight on pressing issues of international relations, as particularly relevant to his experiences working closely with the European Union Commission and EU Parliament on critical transnational security issues.

His participation as the National Security Senior Advisor to the Trump transition team provides him with unique insight into the incoming administration and the next President of the United States. Rogers is a senior fellow at Harvard University, a distinguished fellow and member of the Board of Trustees at the Center for the Study of the Presidency and Congress, a distinguished fellow at the Hudson Institute, and a member of the Advisory Board for George Mason University's National Security and Law Policy Institute.

With his distinct style and candid wit, he offers audiences unparalleled insights and analysis on current events.

### **Darren Buchwald**







Prior to joining Emergent, Mr. Buchwald served as vice president, business development at Clinical Data, Inc. While at Clinical Data, Mr. Buchwald was responsible for leading corporate development efforts that culminated in Forest's acquisition of the company. Prior to joining Clinical Data, Mr. Buchwald served in leadership positions at MiddleBrook Pharmaceuticals and Human Genome Sciences. Mr. Buchwald's experience includes over 25 years of pharmaceutical experience in strategy, business development, marketing, and sales at development- and commercial-stage biopharmaceutical companies.

Mr. Buchwald earned a B.A. in speech communication from The University of Maryland.



### Adam R. Havey







Mr. Havey joined Emergent BioSolutions in 2003 and has served as executive vice president, business operations since April 2017. He previously served as executive vice president and president, biodefense division from March 2011 to March 2017. Prior to that, Mr. Havey has held various roles including president of Emergent Biodefense operations Lansing from January 2009 to February 2011, vice president of business Operations from November 2007 to December 2008, senior director of manufacturing development from June 2006 to November 2007, director of facilities, resource planning and security operations from February 2005 to June 2006, and project manager from July 2003 to February 2005.

Prior to joining Emergent, Mr. Havey served in product development for Eli Lilly. He received a B.S. degree in chemical engineering from Michigan State University.

### Laura Saward, Ph.D.





### Senior Vice President, Antibody Therapeutics Business Unit Head

Dr. Saward joined Emergent BioSolutions in 2014 through the acquisition of Cangene Corporation and has served as senior vice president, antibody therapeutics business unit lead since April 2017. Prior to this position, Dr. Saward was vice president of research and development from April 2014 to April 2017. Before joining Emergent, Dr. Saward held various leadership roles at Cangene including chief scientific officer and vice president of research and development from April 2012 to April 2014, and senior director of bioanalytical research from October 2010 to April 2012, which provided her the opportunity to direct the licensure of multiple products for commercial markets and government contracts for the Strategic National Stockpile.

Prior to joining Cangene, Dr. Saward's career included positions in start-ups, mid-size and larger pharma companies including Cardiovascular Sciences Inc., Viventia Biotech, Syntex and Johnson & Johnson.

Dr. Saward received her B.Sc. from the University of Guelph and Ph.D. from the Faculty of Medicine at the University of Manitoba. She completed her Post-doctoral Fellowship at Robarts Research Institute, University of Western Ontario. Dr. Saward maintains strong ties to academia through her adjunct professor position at University of Manitoba, Department of Medical Microbiology and Infectious Diseases, and as a member of many key boards in Manitoba including Research Manitoba.

### Doug White







Doug White joined Emergent in 2017 and serves as head of the devices business unit. He previously served as vice president and general manager of Molecular Diagnostics & Women's Health at Becton Dickenson Diagnostics. Before joining Becton Dickenson Diagnostics, he was chief executive officer of OpGen Inc. Mr. White has held several executive leadership positions at multi-national companies including QIAGEN/Digene, where he was responsible for building the commercial organization that helped established the HPV screening market in the US, IGEN International, Bayer/Chiron Diagnostics, and Abbott Diagnostics. Mr. White has extensive experience in operations, portfolio and product management, sales and marketing, and customer and scientific support.

Mr. White holds a Bachelor of Arts in Political Science from Washington College and is a board member of Maryland World Trade Center Institute.

## Sean M. Kirk





Mr. Kirk joined Emergent BioSolutions in 2003 and has served as senior vice president, manufacturing operations and contract manufacturing operations (CMO) business unit lead since April 2017. Prior to this position, Mr. Kirk has held various senior leadership roles including senior vice president, chief operations officer from November 2015 to March 2017, senior vice president of bioscience operations from February 2014 to November 2015 and senior vice president of biodefense vaccines and therapeutics development from March 2012 to February 2014. Mr. Kirk also served in multiple roles of increasing responsibility at Emergent's Manufacturing Operation Site in Lansing, Michigan.


Before joining Emergent, Mr. Kirk worked at Merial, a multinational animal health company, serving in various positions from 1996 to 2001.

Mr. Kirk received both an M.B.A. and B.S. in Microbiology from the University of Georgia.



### W. James Jackson, Ph.D.





Dr. Jackson has served as senior vice president and chief scientific officer since February 2008. Dr. Jackson served as vice president technical support from June 2007 to February 2008 and vice president commercial development from April 2005 to June 2007.

Prior to joining the company, Dr. Jackson served as president, Antex Biologics Research and Development Corporation from January 2004 to May 2005. Dr. Jackson served in various research and development positions at Antex Biologics Inc, a biotechnology company, from March 1997 to December 2003, when we acquired substantially all of the assets of Antex. Dr. Jackson served as director, molecular biology for MicroCarb Inc. from April 1994 to March 1997, and served in various research positions at W.R. Grace & Co. from August 1987 to March 1994. Dr. Jackson has 17 patents issued in his name.

Dr. Jackson received his Ph.D. in Microbiology from the University of Georgia and a B.A. in Microbiology/Biochemistry from the University of Tennessee.



### Barbara Solow, Ph.D.







Dr. Solow has held numerous roles over her ten years at Emergent, including senior vice president of research & development and Gaithersburg site head. She has played a key role in successfully securing more than \$4 billion in funding and in expanding the R&D portfolio from anthrax vaccines to a broad spectrum of medical countermeasures.


From 2006-2008 Dr. Solow was a principal consultant with PRTM, a management consulting firm where she led and worked on teams focused on U.S. government and commercial projects related to healthcare, biotechnology, and biodefense including strategy, implementation of best management practices, portfolio management, end-to-end product development, and proposal management/ preparation. From 2003-2006 Dr. Solow served as director, business development with DynPort Vaccine Company, where in less than three years, she expanded a "one contract" biotechnology company into three new product lines and two new U.S. government agencies by creating an opportunity pipeline, devising a marketing strategy, and then leading a team to win two grants and four contracts from competitive procurements totaling more than \$300 million. Dr. Solow has also held various scientific positions such as senior scientist, DynPort Vaccine Company (2001-2003) and research scientist with the U.S. Department of Agriculture (1998-2001).

Dr. Solow was a postdoctoral research fellow at University of Pennsylvania, where she focused her research on diabetes and insulin signaling. Dr. Solow received her Ph.D. in Biochemistry from Virginia Polytechnic Institute and State University, her Masters in Animal Sciences from the University of Kentucky and her Bachelors in Science from University of Illinois at Urbana-Champaign. She has 13 peer-reviewed publications and a patent.

### **Atul Saran**







Previously, Mr. Saran served in various leadership roles at AstraZeneca and MedImmune from 2003 through 2014, including vice president, corporate development and ventures at AstraZeneca and chairman of the MedImmune Ventures investment committee from May 2013 to January 2014; senior vice president, corporate development and ventures from January 2011 to May 2013; and positions of increasing responsibility in the MedImmune legal department from 2003 through 2010, culminating as vice president and deputy general counsel. Before his time at MedImmune, Mr. Saran was an associate attorney in the business and finance group at Hogan & Hartston.

Mr. Saran is an active board member of LogicNets, Inc. He has served on the board of directors for several other companies including VentiRx Pharmaceuticals, Xencor, Inotek Pharmaceuticals and Arriva Pharmaceuticals.

Mr. Saran holds a J.D. from the University of Illinois College of Law, an M.B.A. from the MIT Sloan School of Management and a B.S. in Biological Sciences from Stanford University.



### Robert G. Kramer, Sr.



#### **Executive Vice President, Administration and Chief Financial Officer**

Mr. Kramer has served as executive vice president, administration and chief financial officer (CFO) since April 2017. He previously served as executive vice president, corporate services division and CFO from September 2012 to March 2017. Mr. Kramer first joined Emergent in 1999 as its CFO. From 1999 until his retirement in 2010, he held various executive positions with the last being president of Emergent Biodefense Operations Lansing. Mr. Kramer returned to the company in 2011 as the interim head of the biosciences division, and then as interim executive vice president, corporate services division.

Prior to joining Emergent in 1999, Mr. Kramer held various financial management positions at Pharmacia Corporation, which subsequently merged with the Upjohn Company in 1995 and eventually became part of Pfizer Inc.

Mr. Kramer received an M.B.A. from Western Kentucky University and a B.S. in industrial management from Clemson University.